TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00881166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + topotecan
Description: Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + docetaxel
Description: Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + erlotinib
Description: 150 mg PO once daily at least 1 hour before or 2 hours after eating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + paclitaxel/carboplatin
Description: Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-470 + carboplatin/etoposide
Description: Carboplatin IV infusion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100 mg/m2 IV infusion over 2 hours on Days 1-3
Study: NCT03555162

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: Imaging examination

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI
Description: Imaging examination
Study: NCT03427411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Flat dose of 1,200 mg of M7824 intravenous (IV) once every 2 weeks
Study: NCT03405311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivanna Accuro 3D Ultrasound Device
Description: The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palpation
Description: The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
Study: NCT04625036

Intervention type: DIAGNOSTIC_TEST
Intervention: Single passive leg movement
Description: The investigation consists of a non-invasive evaluation by ultrasounds performed on the common femoral artery investigating the speed of arterial blood flow \[Leg Blood Flow LBF\] and diameter of vessel with a dedicated ultrasound system (General Electric Medical Systems, Milwaukee, WI) using Doppler method, before and after a passive flexion-extension movement of the knee. A linear probe will be used with a frequency of 5 MHz. Using the diameter of the artery and the average volume (Vmean), the LBF will be calculated every second with the formula=Average volume\*PiGreco\*(vessel diameter / 2)2\*60.~The subject will be placed in a sitting position for 20 minutes before the test. The protocol consists of image acquisition for 60 seconds (basal measurement), followed by a passive flexion-extension of the knee (single passive leg movement). The knee flexion will be performed by health care personnel at a rate of 1 Hz. At the end of the movement, the recording will continue for 60 seconds.
Study: NCT02243748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Therapy
Description: Receive individualized palliative care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00606008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
Study: NCT02106481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Catheters
Description: Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Shot Femoral Nerve Blocks
Description: The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Shot Femoral Nerve Blocks
Description: The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
Study: NCT01715831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
Study: NCT02111018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb Device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVVH
Study: NCT02548871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Outreach Program
Description: TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
Study: NCT00547339

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT)- 45 Gy
Description: Dose of SBRT - 45 Gray (Gy) in five fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT) - 47.5 Gy
Description: Dose of SBRT - 47.5 Gray (Gy) in five fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 1)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy (SBRT) - 50 Gy (Phase 2)
Study: NCT01248455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Anti-KIR)
Description: Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
Study: NCT03829176

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing
Description: Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
Study: NCT02517619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic Solution
Description: 40 mg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate Ophthalmic (1%)
Description: Prednisolone Acetate (1%)
Study: NCT01353534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Antigen
Description: A/H5N1 Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Antigen
Description: A/H5N1 Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Antigen
Description: A/H5N1 Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Antigen
Description: A/H5N1 Antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine Enhancement Patch
Description: Vaccine Enhancement Patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine Enhancement Patch
Description: Vaccine Enhancement Patch
Study: NCT01632319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Motivational Interviewing and Cognitive Behavioral Therapy
Description: 8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
Study: NCT03366753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute normovolemic hemodilution
Description: acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-vitro hemodilution
Description: Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-vitro hemodilution
Description: Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
Study: NCT02271451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Q collar
Description: collar worn around neck
Study: NCT00977197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo will be administered twice a day
Study: NCT03568201

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous oximetry
Description: Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
Study: NCT04117022

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DVS supplementation
Description: Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
Study: NCT03074695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural puncture epidural (DPE)
Description: Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Epidural (EPL)
Description: Standard epidural placement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dural puncture epidural (DPE)
Description: Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Epidural (EPL)
Description: Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
Study: NCT00470548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alimta
Description: Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
Study: NCT03168373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: language rehabilitation therapy
Description: language therapy is language rehabilitation by language therapist during subacute phase in stroke patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: language rehabilitation therapy
Description: language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
Study: NCT03236454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DC-Stimulator MC, NeuroConn
Description: 20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC-Stimulator MC, NeuroConn
Description: 20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
Study: NCT00158353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GirlPOWER! mentoring program
Description: GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional mentoring
Description: Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
Study: NCT04665908

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment by PT/Orth surgeon
Description: Assessment by orthopaedic surgeon or a PT

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment by PT/Orth surgeon
Description: Assessment by orthopaedic surgeon or a PT
Study: NCT02897349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: background therapy
Description: insulin with or without metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: background therapy
Description: insulin with or without metformin
Study: NCT02158897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolon diet
Description: 3 cycles of a 5-day Prolon diet very month
Study: NCT01854814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Maximum tolerated labeled dose of Losartan
Study: NCT01420159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methoxyflurane
Description: Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
Study: NCT00586560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kareniticin and cyclophosphamide
Description: An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kareniticin and cyclophosphamide
Description: An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity.
Study: NCT02789371

Intervention type: PROCEDURE
Group type: OTHER
Intervention: the first pass is made with 5ml suction technique
Description: the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: the first pass is made with modified wet suction technique
Description: the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
Study: NCT03797352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
Study: NCT04664218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIPEC device
Description: To report the affordability on using the HIPEC machine of our design compared to the standard ones in poor places.
Study: NCT02917746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Large Loop Excision of the Transformation Zone
Description: Patients in this group are treated with LLETZ.
Study: NCT04894058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ureteroscopic lithotripsy
Description: After combined spinal and epidural anesthesia, patients were subjected to low pressure perfusion; The semirigid ureteroscope was passed through the urethra to the bladder, after which both ureteral orifices were observed. A 0.035 soft-tipped guidewire was sent through the ureter orifice and reached the renal pelvis. Subsequently, the patients were placed in the reverse trendelenburg position by leaning 10 ° or 20 ° with their head up and hips down or standard lithotomy position. The ureter stone was accessed with a semirigid ureteroscope. A 273 micron Holmium: yttrium-aluminum-garnet (Ho: YAG) laser was applied as an energy source set at 1.0 J and a speed of 8-10 Hz.